BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease

Not Applicable

Completed

Conditions: May-Thurner Syndrome
Venous Disease
Iliofemoral Occlusive Disease
Peripheral Vascular Disease

Interventions: Device: VENOVO™ Venous Stent

Registration Number: NCT02655887

Lead Sponsor: C. R. Bard

Brief Summary: The BARD® Venovo™ Venous Stent Study is a non-randomized clinical study intended to collect confirmatory evidence of the safety and effectiveness of the Venous Stent for the treatment of iliofemoral occlusive disease.

Detailed Description: This is a prospective, multi-center, non-randomized, single-arm clinical study of the VENOVO ™ Venous Stent for the treatment of iliofemoral occlusive disease. The study will be conducted at a maximum of 35 investigational sites ("sites") in the United States, and Europe and Australia/New Zealand. Enrollment will continue until a maximum of one hundred seventy (170) subjects are treated with the VENOVO™ Venous Stent, which is an estimated three-hundred forty (340) consecutive subjects in a non-randomized fashion. It is assumed that approximately 50% of the treated subjects will be U.S. subjects. Clinical follow-up for all treated subjects will be performed at hospital discharge, 30-days, and 6-, 12-, 24-, and 36-months post-index procedure.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 170

Inclusion Criteria

The subject provides written informed consent using an Informed Consent Form approved by Ethics Committee/ Institutional Review Board for the site.
Subject agrees to comply with the protocol-mandated follow-up procedures and visits.
The subject is a male or non-pregnant female ≥ 18 years old with an expected lifespan sufficient to allow for completion of all study procedures.
The subject has symptomatic (non-malignant) venous outflow obstruction in iliofemoral "venous segments".
The subject has symptomatic venous outflow obstruction (non-malignant) in iliofemoral venous segments(Clinical-Etiology-Anatomic-Pathophysiologic (CEAP) "C" ≥ 3 or VCSS pain score of ≥ 2).
The subject is able and willing to comply with any required medication regimen.
The reference vessel diameters are between 7mm and 19 mm.

Exclusion Criteria

Subject is unable or unwilling to provide written informed consent, or is unable or unwilling to conform to the study protocol follow-up procedures and visits.
Subject is or plans to become pregnant during the study.
Subject has contralateral disease of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof and does not meet the venous outflow obstruction requirement or has a malignant obstruction.
The subject is asymptomatic, has a CEAP "C" <3, or a VCSS pain score of <2.
The subject has a venous obstruction that extends into the inferior vena cava (IVC) or below the level of the lesser trochanter.
The subject has a known uncorrectable bleeding diathesis or active coagulopathy.
The subject has a known allergy or sensitivity to Nickel or Titanium or intolerance to antiplatelet, anticoagulant or thrombolytic medications medications required per the protocol
The subject has a known allergy or sensitivity to contrast media, which cannot be adequately pre-medicated.
The subject has any planned surgical interventions within 30 days prior to, or within 30 days after the planned study procedure.
The subject has a lesion or occlusion which cannot be traversed with a guidewire.
The subject has had prior stenting in the target vessel.
The subject has iliofemoral venous segments unsuitable for treatment with available sizes of study devices.
The subject has another medical condition, which may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow completion of study procedures and follow ups.
The subject is currently participating in an investigational drug, biologic, or another device study.
The subject is currently on dialysis or has a serum creatinine ≥2.5mg/dl.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
VENOVO™ Venous Stent.	VENOVO™ Venous Stent	Implant of the VENOVO™ Venous Stent

Primary Outcome Measures

Name	Time	Method
Number of Participants With Primary Patency of the Venous Stent at 12 Months Post-Index Procedure	12 months post-index procedure	Primary patency rate at 12 months post-index procedure evaluated against a literature-derived Performance Goal (PG) of 74%. Primary patency defined as: freedom from Target Vessel Revascularization (TVR); freedom from thrombus occlusion and stenosis \> 50% as measured by Duplex Ultrasound (DUS). Please note that both the primary effectiveness and the primary safety endpoint are considered co-primary endpoints. That is, both endpoints need to be significant to claim the study as successful.
Number of Participants With Freedom From Major Adverse Events (MAEs)	30 days post-index procedure	Freedom from major adverse events (MAEs) defined as: Target Vessel Revascularization; Device and/or procedure related death; Major amputation of target limb; Pulmonary Embolism which is clinically important; Vascular injury requiring surgical/endovascular intervention; Embolization /migration of stent; Device or procedure related acute DVT involving the treated limb. Please note that both the primary effectiveness and the primary safety endpoint are considered co-primary endpoints. That is, both endpoints need to be significant to claim the study as successful.

Secondary Outcome Measures

Name	Time	Method
Endpoint Without Hypothesis Testing: Index of CEAP at 30 Days, 6 Months, and 12 Months Post Procedure	Evaluation through 30 day, 6 months and 12 months post index procedure	Clinical-Etiologic-Anatomic-Pathophysiologic (CEAP) Classification is a system that describes a doctor's physical exam findings for vein problem(s), the cause of the problem(s), the location in the leg, and the mechanism responsible for the manifestation of the vein problem. For Clinical classification, the clinical components indicates disease severity, ranging from none (0 points) to active ulcers (6 points).For each category of Etiology, Anatomy, and Pathophysiology classifications, at each time point, frequency of each category is reported. Subsequent clinical study reports will present CEAP at 24 and 36-months follow-up. Changes from baseline measures to given time points are presented. Lower mean scores represent an improvement from baseline measure.
Endpoint With Hypothesis Testing: Index of Venous Clinical Severity Score (VCSS) From Baseline to 12 Months	Evaluation at 12 months post-index procedure	The Venous Clinical Severity Score (VCSS) system includes 10 clinical descriptions (pain, varicose veins, venous edema, skin pigmentation, inflammation, induration, number of active ulcers, duration of active ulceration, size of active ulceration. and level of compliance with medical compression therapy), scored from 0 to 3 (total possible score, 30) with 0 means absent, 1 means mild, 2 means moderate and 3 means severe. Total VCSS is the sum of all VCSS assessment scores from categories for a given time point. Twelve-month data is the change between baseline score and 12-month follow-up score. Results calculated for Intent-to-Treat (ITT) subjects. Lower values represent a better outcome, that is, a level of pain less than that experienced at baseline.
Endpoint With Hypothesis Testing: Index of Quality of Life (QoL) From Baseline to 12 Months	Evaluation at 12 months post-index procedure	The Quality of Life (QoL) assessment of Chronic Venous Insufficiency Questionnaire (CIVIC-20) is a 20-item questionnaire which provides a global index and an outline of 4 QoL dimensions - pain (4 items), physical (4 items), psychological (9 items) and social (4 items). Items are scored on a scale from 1 to 5. A low score corresponds to greater patient comfort. Total CIVIQ-20 score is the sum of all 20-item scores The score of each dimension was obtained by adding up the scores of each constituent item within that dimension. Twelve-month data is the change between baseline score and 12-month follow-up score. Results calculated for evaluable ITT subjects. Lower values represent a better outcome, that is, a better QoL than that experienced at baseline.
Endpoint Without Hypothesis Testing: Number of Participants With Lesion Success (ITT Subjects)	At the conclusion of index procedure	Lesion Success is defined as the attainment of less or equal to 50% residual stenosis at the conclusion of the index procedure.
Endpoint Without Hypothesis Testing: Number of Participants With Freedom From Target Lesion Revascularization (TLR) (ITT Subjects)	Evaluation throrugh 30 day, 6 months and 12 months post index procedure	Freedom from Target Lesion Revascularization (TLR) through 30 days is specific to the first revascularization procedure of the target lesion.
Endpoint Without Hypothesis Testing: Number of Participants With Freedom From Target Vessel Revascularization (TVR) (ITT Subjects)	Evaluation through 30 days, 6 months and 12 months post index procedure	Freedom from Target Vessel Revascularization (TVR) is defined as the first revascularization procedure of the target vessel, as determined by an Independent Core Lab. Freedom from Target Lesion Revascularization (TLR) and Freedom from TVR results are the same through the 12 month analysis as all TLRs were also TVRs in this case.
Endpoint Without Hypothesis Testing: Number of Participants With Acute Technical Success	At time of Index Procedure	Acute technical success is defined as successful deployment of stent(s) to intended target with adequate lesion coverage as assessed by the Investigator.
Endpoint Without Hypothesis Testing: Number of Participants With Acute Procedure Success (ITT Subjects)	Less than 30 days post index procedure	Technical success is defined as no major adverse events experienced between index procedure and discharge
Endpoint Without Hypothesis Testing: Number of Participants Without Device Stent Fracture at 12 Months Follow-Up	Evaluation at 12 months post-index procedure	Stents were evaluated at the 12 month follow-up for fracture analysis. Evaluable ITT subjects are included in this analysis.

Trial Locations

Locations (21): Cox Medical Centers
🇺🇸
Springfield, Missouri, United States
Yale University
🇺🇸
New Haven, Connecticut, United States
JMLS Medical Services PTY LTDT/A PERTH INST. of VASCULAR RESEARCH
🇦🇺
Perth, Western Australia, Australia
Vascular Breakthroughs, LLC
🇺🇸
Darien, Connecticut, United States
Mount Sinai Medical Center
🇺🇸
New York, New York, United States
Cardiothoracic and Vascular Surgeons
🇺🇸
Austin, Texas, United States
Midwest Cardiovascular Research Foundation
🇺🇸
Davenport, Iowa, United States
Metro Health Hospital
🇺🇸
Wyoming, Michigan, United States
North Carolina Heart and Vascular
🇺🇸
Raleigh, North Carolina, United States
Sentara Medical Group
🇺🇸
Virginia Beach, Virginia, United States
Lake Washington Vascular, PLLC
🇺🇸
Bellevue, Washington, United States
Royal Prince Alfred Hospital
🇦🇺
Camperdown, New South Wales, Australia
Centra Health, Inc., dba Stroobants Cardiovascular Center
🇺🇸
Lynchburg, Virginia, United States
University Hospital Galway
🇮🇪
Gaillimh, Ireland
Universitaets-Herrzentrum Freiburg-Bad Krozingen
🇩🇪
Bad Krozingen, Germany
Uniklinik RWTH
🇩🇪
Aachen, Germany
CAMC Health Education and Research Institute
🇺🇸
Charleston, West Virginia, United States
Klinikum Arnberg
🇩🇪
Arnsberg, Germany
Fundacion de investigacion HM Hospitales
🇪🇸
Madrid, Spain
MUMC Maastricht
🇳🇱
Maastricht, Netherlands
Guy's & St. Thomas' Hospital
🇬🇧
London, United Kingdom